参苓白术颗粒联合吉非替尼对晚期非小细胞肺癌的治疗作用

摘要

Objective Observation of Shenling Baizhu granule combined with gefitinib in advanced non small cell lung can-cer (NSCLC ) treatment effect .Methods Select diagnosed by pathology or cytology of 40 cases of NSCLC patients ,were ran-domly divided into treatment group and control group ,the patients in the treatment group received oral Shenling Baizhu parti-cles ,6 g/3 times/d ,gefitinib 250 mg/d orally;the control group only received gefitinib 250 mg/d orally ;the two groups were treated for 21 d as 1 chemotherapy cycle ,at least 3 cycles of treatment .A comparison of the short-term efficacy ,quality of life ,the two groups of patients with clinical symptoms improvement and the changes of T cell subset .Results No signifi-cance between the two groups of curative effect in the near future ( P>0 .05 );the treatment group after treatment ,KPS score ,quality of life to improve the clinical curative effect of TCM syndrome was significantly higher than that in control group ( P<0 .05 ) .The treatment group CD4 after treatment than before treatment ( P<0 .05 ) increased .Conclusion Large headed Atractylodes granule combined with gefitinib can significantly improve the life quality of patients with advanced NSCLC ,regulate immune function .%目的：观察参苓白术颗粒联合吉非替尼对晚期非小细胞肺癌（NSCLC ）的治疗效果。方法选取经病理组织学或细胞学确诊为NSCLC患者40例，随机分为治疗组及对照组。治疗组患者给予参苓白术颗粒口服，6 g／次，3次／d ，吉非替尼250 mg／d口服；对照组仅给予吉非替尼250 mg／d口服。2组均连续治疗21 d为1个化疗周期，至少治疗3个周期，对比2组患者近期疗效、生活质量、中医症状改善及T细胞亚群变化。结果2组近期疗效比较无统计学意义（P＞0.05）；治疗组治疗后生活质量KPS评分改善，中医证候临床疗效显著高于对照组（ P＜0.05），治疗组治疗后CD4较治疗前升高（ P＜0．05）。结论参苓白术颗粒联合吉非替尼可显著改善晚期NSCLC患者生活质量，调节免疫功能。